Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jun 02 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received tentative approval from the USFDA for Rifaximin Tablets, which are used to treat irritable bowel syndrome with diarrhoea in adults. The approval allows Zydus to produce these tablets at its manufacturing site in Ahmedabad. The press release highlights that Rifaximin tablets had significant annual sales in the United States, indicating a strong market potential for the product.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases